Compare TSLX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | NVAX |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | United States |
| Employees | N/A | 749 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2011 | 1996 |
| Metric | TSLX | NVAX |
|---|---|---|
| Price | $18.06 | $10.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $19.77 | $14.00 |
| AVG Volume (30 Days) | 363.2K | ★ 4.4M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.82% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.99 | N/A |
| P/E Ratio | $122.30 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $16.04 | $6.20 |
| 52 Week High | $23.19 | $11.85 |
| Indicator | TSLX | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.69 | 66.82 |
| Support Level | $17.20 | $8.42 |
| Resistance Level | $18.59 | $10.85 |
| Average True Range (ATR) | 0.33 | 0.51 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 34.95 | 85.83 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.